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Background/aim: Idiopathic granulomatous mastitis is a rare, benign inflammatory disease of breast. There is no general agreement
on the appropriate treatment choice. The aim of the study was to investigate the immunosuppressive administer for idiopathic
granulomatous mastitis and risk factors related with disease recurrence.
Materials and methods: The data of 53 patients with idiopathic granulomatous mastitis were evaluated for this cross-sectional
retrospective study. Demographic features and clinical characteristics and course of the patients were obtained from file records.
Results: The mean age of the patients was 37.2 ± 6.6 years. Fifty-one of 53 patients received immunosuppressive treatment with or
without surgery. Forty-seven (88.6%) of the patients received only immunosuppressive treatment without surgery, while 4 (7.54%)
patients received immunosuppressive treatment after surgery. Forty-one (77.3%) of 47 patients who had no surgical resection received
methotrexate as immunosuppressive treatment. The other 6 (11.3%) patients received azathioprine or corticosteroid treatment.
Complete or partial remission was observed in 50 (98%) of 51 patients who received immunosuppressive treatment, while only 1 (2%)
patient did not reach remission. No factors were found related with recurrence of disease.
Conclusion: Methotrexate seems to be efficient in the treatment of idiopathic granulomatous mastitis and provides drug-free remission.
Key words: Azathiopurine, idiopathic granulomatous mastitis, methotrexate, treatment

1. Introduction
Idiopathic granulomatous mastitis (IGM) is a rare and
benign chronic inflammatory disease of breast with an
unknown etiology [1]. Due to clinical presentations
(mass, erythema, swelling, fistula formation) and
radiological findings (abscess formation, enlarged
lymph nodes, hypoechoic lesions, calcifications, and
asymmetric increased density), it may be confused
with carcinomas or infections [2]. Histopathological
examination is warranted to show noncaseating
granulomatous lobulitis. Diseases which may cause
chronic granulomatous lobulitis such as tuberculosis,
granulomatous with polyangiitis, and sarcoidosis should
be excluded before the patients were diagnosed with IGM.
In the literature, there is limited data about treatment
approach of IGM [3,4]. Surgery and/or medical therapy
including antibiotics and immunosuppressive agents
are treatment choices, as well as there is no established
treatment algorithm for IGM [5,6]. This study aims to
investigate the treatment choices and follow up data of
the patients with IGM.

2. Materials and methods
2.1. Study design, sample, and setting
This retrospective study was conducted in a tertiary
rheumatology outpatient clinic. It was approved by the
Ethical Review Board of Gülhane Training and Research
Hospital.
A total of 53 patients who had noncaseating
granulomas and were diagnosed with IGM after physical
examination and histopathologic evaluation of the breast
biopsy samples were included in the study. The patients
were followed up in our outpatient clinic between February
2011 and September 2018. The patients diagnosed with
other granulomatous diseases were excluded. All of the
patients included in the study were female due to the higher
frequency of disease among female patients. Informed
consent form was obtained from each participant.
2.2. Data collection
Demographic and clinical data were obtained
retrospectively from patient files. The treatment options
applied (antibiotics, steroids, immunosuppressive drugs,
or surgical intervention), the duration, course, and
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outcomes of treatment for each patient were investigated.
Treatment efficiency was evaluated with clinical
improvement and partial or complete remission. In the first
month visit, presence of any improvement in symptoms,
physical findings, and acute phase reactants were accepted
as clinical improvement. The presence of at least 50%
improvement in clinical and radiological findings at 3rd or
6th month visits was accepted as partial remission. Besides,
complete recovery in clinical and radiological findings at
6th month visit was accepted as complete remission.
2.3. Data analysis
For statistical analyses, IBM SPSS 24 software for Windows
(SPSS Inc., Chicago, Illinois) was used. Descriptive
statistics were presented as mean ± standard deviation
and median (minimum–maximum) values for measured
variables, and frequency and percentage (%) for categorical
data. Categorical variables of the patients with or without
recurrence were compared by using Pearson’s chi-squared
test and Fisher’s exact test as appropriate. A value of P <
0.05 was accepted as statistically significant.
3. Results
All patients included in the study were female in
childbearing age. The mean age was 37.2 ± 6.6 years. The
median time to be diagnosed with IGM was 4.37 months
(range: 0.7–144 months) and median time of follow-up
was 13.83 months (range: 1.61–100.83 months). Fifty
(94.3%) patients were diagnosed within the first 2 years
of breastfeeding. At the time of diagnosis, three (5.6%)
patients were pursuing breastfeeding and one (1.8%)
patient was pregnant. The most common symptom in the
admission was palpable mass in the breast in all of the
patients. Other symptoms were changes on the skin of
breast in 38 (71.7%), fistula and purulent discharge in 30
(56.5%), and ulceration on the skin of breast in 11 (20.8%)
patients. Among 25 (47.2%) patients, the left breasts were
influenced, whereas among 23 (43.4%) patients the right
breasts and in 5 (9.4%) patients both of them were affected.
Axillary reactive lymphadenopathies were detected in 21
(39.6%) of the patients. Detailed demographic and clinical
data of the patients were presented in Table 1.
Initial treatment options applied to the patients were
presented in Table 2. Forty-seven (88.7%) patients received
only immunosuppressive treatment, 4 (7.5%) patients
received immunosuppressive treatment following surgical
intervention, and one (1.9%) patient underwent surgical
resection without any immunosuppressive treatment.
Only one (1.9%) patient denied receiving treatment.
Among
47
patients
who
received
only
immunosuppressive drugs for initial treatment, 41 (77.4%)
received methotrexate (MTX) and corticosteroids (CS), 3
(5.7%) received azathioprine (AZA) and CS, and 3 (5.7%)
received only CS. Surgical intervention was performed as

initial treatment for 5 (9.4%) patients. Median doses of
MTX, AZA, and CS were 15 mg/week, 125 mg/day, and 40
mg/day, and median durations of treatment were 9.1, 5.61,
and 9.63 months, respectively.
Clinical improvement was observed in the first month
of the treatment in all of 41 patients who received MTX
and CS for the initial treatment. Among the 41 patients
who received MTX for initial treatment, 36 (87.8%)
continued receiving MTX throughout the treatment
process. Thirty-three (80.5%) of those 36 patients were
found to be in sustained remission in the follow-up visits.
Median time of achieving remission was 13.04 months
(range: 1–62 months). After remission, 3 (9.1%) patients
were followed up with only MTX, 16 (48.5%) patients with
MTX and CS, and 14 (42.4%) patients were followed drugfree. On the other hand; 3 (7.3%) patients were accepted
to be in partial remission according to the improvement
of clinical symptoms, in spite of short treatment durations
(shorter than 6 months). During follow-up visits, recurrent
disease was detected in both clinic and ultrasonographic
evaluations of 5 (12.2%) patients who were receiving MTX.
Recurrence was determined in 4 (9.8%) patients at 3rd
month of the treatment process. Clinical and radiological
recurrences were detected in all these 5 patients at 6th
month of treatment. One (2.44%) of them treated with
higher doses of MTX and CS, and treatments of other 4
(9.76%) patients were switched to AZA. The mean time of
switching from MTX to AZA was 8.72 ± 2.3 months. In two
(4.88%) patients whose treatments were switched to AZA
due to the presence of recurrence, remission was observed
in 10th and 26th months of the treatment process. One
patient had gastrointestinal symptoms with MTX, and
the treatment was switched to AZA. This patient also had
remission with AZA treatment.
Two of three patients (66.7%) who received AZA and
CS for initial treatment had clinical improvement in the
first month of therapy and no recurrence was seen during
follow-up visits. These two patients achieved both clinical
and radiological remissions in 6th and 9th months of
the treatment duration, respectively. One patient had
progression of clinical symptoms. Due to concomitant
Sjogren’s syndrome and thrombocytopenia in this patient,
cyclosporine-A was applied. In total of 7 patients who
received AZA, complete remission was observed in five
(71.4%) and partial remission was observed in 2 (28.6%)
patients. Median time for remission was 9.33 months
(range: 6–26 months). Treatment of AZA could be
withdrawn in none of the patients.
Three (5.7%) patients received CS for initial treatment.
All of these patients had clinical improvement in the 1st
month of the treatment. All of the patients’ clinical and
radiological remissions were observed in a median time
of 9.63 months (range: 1–13 months). Among these 3
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Table 1. Demographic and clinical characteristics of the patients (n = 53).
Patients’ characteristics

Value

Age, years

37.2 ± 6.6

†

Disease duration, months‡

4.37 (0.7–144)

Follow-up duration, months

13.83 (1.61–100.83)

Body mass index, kg/m , n (%)
≥ 30
25-30
<25

12 (22.6)
29 (54.8)
12 (22.6)

Smoker, n (%)

20 (37.7)

Number of pregnancies
0
1
>1

3 (5.7)
13 (24.5)
37 (69.8)

Patients using contraception, n(%)
Oral contraceptive pills
Intrauterine device

21 (39.6)
12 (22.6)
9 (17.0)

Main complaint, n (%)
Palpable mass
Skin changes (erythema, nipple inversion, induration)
Fistula formation and purulent drainage
Ulceration
Axillary lymphadenopathy

53 (100)
38 (71.7)
30 (56.5)
11 (20.8)
21 (39.6)

Affected breast, n (%)
Unilateral- left
Unilateral- right
Bilateral

25 (47.2)
23 (43.4)
5 (9.4)

‡

2

mean ± standard deviation, ‡median (minimum–maximum), other values are
presented as percentage
†

Table 2. Initial treatment approaches of the patients.
n

%

Surgical intervention

5

9.4

Only surgery

1

1.9

Immunosuppressive treatment after unsuccessful surgery

2

3.8

Immunosuppressive treatment with surgery

2

3.8

Immunosuppressive drugs

47

88.7

Only corticosteroids

3

5.7

Methotrexate and corticosteroids

41

77.4

Azathioprine and corticosteroids

3

5.7

No treatment

1

1.9

patients, CS treatment was stopped for one and tapered in
the follow-up period of the other two patients.
After surgical invention, 4 patients had received
MTX. Two of the patients received MTX after operation
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and the other two had recurrence after surgery and
MTX was started after recurrence. One patient used no
immunosuppressive treatment after surgery. Relapse
after surgery was observed in all of 3 patients who had
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no immunosuppressive treatment. The longest remission
time after surgical intervention was 32.75 months
without immunosuppressive treatment. Although one
patient had no treatment (either medical or surgery),
clinical and radiological remission were achieved after 12
months follow-up. After 64 months follow-up, a sustained
remission was observed in this patient.
Fifty-one patients had immunosuppressive treatment
for IGM. Complete remission was seen in 45 (88.2%),
partial remission was seen in 5 (9.8%), and no remission
was seen in 1 (2%) of the patients. Median time for
remission was 11.99 months (range: 1–62 months).
Clinical and radiological responses of the patients were
shown in Table 3.
Factors related with disease recurrence were
investigated. No statistically significant difference in
terms of smoking, parity, body mass index, and use of oral
contraceptive pills was detected between recurrent IGM
and nonrecurrent IGM groups (P values were 0.748, 1.0,
0.711, and 0.743, respectively).
4. Discussion
IGM is known to be a rare and benign inflammatory
disease of breast tissue, although the etiology remains to
be unclear [7]. Despite the increasing frequency of patients
diagnosed with IGM in recent years, there is still limited
data about the clinical course and management of the
disease.
IGM primarily affects young women in the lactation
period [8]. Lactational secretions may cause a local
granulomatous reaction [9]. Also, pituitary adenoma
(prolactinomas) and some drugs (e.g., antipsychotics)
may increase intraductal secretion. Although exact
etiological factors are not clarified yet, obesity, smoking,
oral contraception pills, ethnicity, and infectious agents
are suspected as etiological factors [10].
IGM may cause ulcers or abscess and mimic
breast cancer. Breast biopsy is needed to clarify
histopathological examination in order to exclude cancers
or infections. Biopsy findings typically include noncaseous
granulomatous lesions with leukocytosis, epithelioid cells,

and macrophages, located in the center of breast lobule
[11]. Although IGM is accompanied with noncaseous
necrosis, acid-fast staining technique and tissue culture
should be performed especially in tuberculosis-endemic
areas [12]. In the present study, tissue biopsy and culture
are performed for all patients to exclude diseases other
than IGM.
In the current study, all of the patients had unilateral
palpable mass in the breast; skin changes of the breast and
fistula formation were the other two common symptoms.
These findings were similar to those in the literature
[13,14]. All patients underwent mammography, breast
ultrasonography (USG), and magnetic resonance imaging
(MRI) as radiological evaluation at the time of diagnosis.
USG and MRI findings provide important information
about IGM [15]. Mammography may demonstrate masses
which lead to asymmetrical increase in the density of the
breast and axillary lymphadenopathies. Ultrasonography
may show multiple confluent, irregular, hypoechoic
masses. Frequently, fistula or abscess formation may be
observed in USG or MRI. Irregular heterogeneous lesions
and parenchymal distortion with a hyperintense signal
on T2-weighted and a variable signal on T1-weighted
images are MRI findings of IGM [15]. However, none of
these imaging modalities are superior to biopsy in the
diagnosis of IGM [7]. Radiological evaluation is important
in diagnosis as well as in follow-up visits. In this study,
all patients were evaluated with USG initially, at 6th and
12th months. Both clinical and radiological regression was
evaluated during follow-up of the patients.
Although there are multiple approaches regarding
the management of IGM in the literature, there is
no clear consensus for treatment. Treatment options
include antibiotherapy, surgical excision, and systemic
immunosuppressive agents such as CS, MTX, and AZA.
Although IGM is a benign, self-limiting disease, disease
recurrence is reported to be approximately 50% among
the patients who had not received treatment [16]. In
our study, one patient accepted neither surgical nor
immunosuppressive treatment. In this patient, remission
was observed after 12 months. The patient was followed

Table 3. Responses of the patients during follow-up.
Initial

1st month
follow-up

3rd month
follow-up

6th month
follow-up

Palpable mass, n (%)

53 (100)

1 (1.9)

5 (9.4)

19 (35.8)

Skin changes, n (%)

38 (71.7)

1 (1.9)

5 (9.4)

4 (7.5)

Ulceration, n (%)

11 (20.8)

0

0

0

Fistula formation and purulent drainage, n (%)

30 (56.5)

1 (1.9)

1 (1.9)

0

Diameter of mass, mean ± SD

2.5 ± 1.0

1.2 ± 0.5

0.5 ± 0.3
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closely because of the high relapse rate in the literature
and no recurrence observed during the follow up period
of 64 months. Many centers prefer empirical antibiotic
therapy at the beginning or concurrent with surgery in
case of the abscess formation and open draining sinuses.
The relationship between IGM and Corynebacterium
infection was presented in the literature and antibiotic
therapy seems to be effective in these cases [9,17]. In
our study, 30 (56.6%) patients with fistula formation and
purulent drainage received antibiotic therapies, but no
improvement was detected. Tests for Corynebacterium
in these patients were also negative. On the other
hand, most common complications of unsuccessful
surgical operations are relapse, fistula formation, and
secondary infection [18]. In our study, 5 (9.4%) patients
underwent surgical intervention and, 3 of them received
no immunosuppressive treatment after surgery. Disease
recurrence was reported in these 3 patients.
The
most
commonly
chosen
systemic
immunosuppressive drugs are CS, MTX, and AZA in the
treatment of IGM [19]. Studies in the literature have shown
that CS treatment may be effective in reducing the size of
the mass and improving abscess formation in patients with
IGM [20–23]. However, many side effects can be observed
with long-term and high-dose CS treatment. Additionally,
studies in the literature reported that approximately 50%
recurrence rate is possible while decreasing the dosage of
CS [24]. In our clinic, 40–60 mg/day prednisolone therapy
for initial treatment is usually preferred. After evaluating
the clinical response within 2–4 weeks, MTX is added
to CS treatment and CS dose is reduced rapidly. After
remission, immunosuppressive treatment can be stopped
in 16–24 months. This approach allows minimizing side
effects associated with CS treatment.
In the literature there are studies showing the
effectiveness of MTX in reducing disease recurrence,
decreasing CS dose as well as providing disease remission
[5,19,25,26]. Regarding a review which analyzed treatment
of IGM patients retrospectively, implementation of MTX
is effective in suppressing inflammation, preventing
complications and reducing the side effects of CS [3]. As
shown in the current study, MTX seems to be efficient
in reducing disease recurrence and providing drug-free
remission. Furthermore, to the best of our knowledge,
our cohort consisting of 51 patients receiving systemic
immunosuppressive therapy is the largest sample in the
literature. Similarly, Konan et al. showed the effectiveness
of AZA in the treatment of IGM [27]. In our study, among
the 7 patients who were treated with AZA due to pregnancy
or MTX-resistant disease, remission was observed in 5
patients.
In our study, 5 patients were considered to have partial
remission. Actually, there is no exact definition about
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partial remission in IGM patients. In our clinic practice,
patients who had improvement in clinical and radiological
sign and symptoms by 50% and above were accepted as
in partial remission, according to the evaluation in 3rd
and 6th months. However, patients with partial response
were indeed the patients with short follow-up period.
The frequency of complete response may increase with
the extension of follow-up duration. Besides, it may be
speculated that expecting higher response rates in longer
follow-up duration will not be surprising.
Previous studies have indicated that breastfeeding
may be the main factor responsible for IGM, especially in
reproductive age [9,19]. In the current study, 50 (94.3%)
of the patients had a history of one or more pregnancies
and all of these patients had the diagnosis of IGM in
the first 2 years following breastfeeding onset. Twelve of
50 patients who have at least one pregnancy history had
disease recurrence. It is found that there is no difference
in parity and breastfeeding between the groups in relation
to recurrence. According to a study performed by Uysal et
al., breastfeeding and pregnancy were suggested to be risk
factors for recurrence of IGM [13].
Oral contraceptive pills are known to be one of the risk
factors for IGM, in relation with increased secretion from
the breast. Hanna et al. showed that patients with chronic
mastitis had higher rates of contraception utilization
than the control group [14]. In our study, 21 (39.6%)
patients were using oral contraceptive pills or hormonal
intrauterine device for contraception. The frequency
of contraceptive pills was found to be higher than other
contraception methods, similar to the literature [14].
Among 21 patients who were using oral contraceptive
pills or intrauterine hormonal devices, 4 had recurrent
disease. There was no statistically significant association
between recurrence of IGM and contraception utilization,
consistent with previous research [13,28].
In recent studies, smoking was reported as an effective
factor in the etiology of IGM [4,10,29]. Although there
were 20 patients who were smokers, the number of patients
with recurrent disease was 5. No statistically significant
difference was found in terms of smoking between
recurrent and nonrecurrent groups. Likewise, Yilmaz et
al. showed that smoking was not significantly different
between groups with or without recurrence [28]. On the
other hand, Uysal et al. and Co et al. investigated the role
of smoking in the recurrence of disease and according to
the findings of both studies, smoking is a prognostic factor
for IGM recurrence [13,28,30].
There were 12 patients with BMI above 30. Two of them
had recurrence of disease and there was no statistically
significant difference in terms of obesity between recurrent
and nonrecurrent groups. To our knowledge, there is no
data in the literature investigating the relationship between
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obesity and IGM. Actually, there is limited data in the
literature investigating the factors related with recurrence
of IGM.
In our clinic, we prefer MTX treatment as a CS tapering
agent in initial treatment. AZA is preferred for the patients
for whom MTX is not appropriate. We obtained complete
remission in 45 (88.2%) of 51 patients who were receiving
immunosuppressive treatment. According to the current
study, MTX seems to be an effective choice for providing
rapid tapering of the steroid dose, and drug-free remission.
Systemic immunosuppressive drugs are important
in the management of patients with IGM. Addition

of MTX to CS therapy can be efficient in reducing CS
dose, controlling the inflammatory process, providing
remission, and preventing further complications. Surgical
treatment may be conceivable for patients with recurrent
or drug-resistant disease. The main limitation of our study
is its retrospective design. Further studies with larger
sample and prospective design are needed to confirm the
efficacy of systemic immunosuppressive therapies in the
treatment of IGM.
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